Silo Pharma, Inc. (SILO)
| Market Cap | 7.19M +242.4% |
| Revenue (ttm) | 72,102 |
| Net Income | -4.84M |
| EPS | -6.80 |
| Shares Out | 1.08M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 19,474 |
| Open | 6.53 |
| Previous Close | 6.44 |
| Day's Range | 6.49 - 6.75 |
| 52-Week Range | 3.32 - 15.15 |
| Beta | 0.75 |
| Analysts | Buy |
| Price Target | 150.00 (+2,162.44%) |
| Earnings Date | May 14, 2026 |
About SILO
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. In addition, the company is developing SP-26, a t... [Read more]
Financial Performance
In 2025, Silo Pharma's revenue was $72,102, a change of 0.00% compared to the previous year's $72,102. Losses were -$4.23 million, -3.76% less than in 2024.
Financial StatementsAnalyst Summary
According to one analyst, the rating for SILO stock is "Buy" and the 12-month stock price target is $150.0.
News
Silo Pharma Inc trading halted, news pending
19:50 EDT Silo Pharma (SILO) Inc trading halted, news pending
Silo Pharma files provisional patent for ibogaine-based therapeutics
Silo Pharma (SILO) announced a strategic initiative to explore ibogaine-based therapeutics for the treatment of traumatic brain injury and associated neuropsychiatric conditions. Silo has filed a prov...
Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury
New initiative from Silo Pharma designed to align with federal actions to accelerate mental health innovation using psychedelic medicines
Silo Pharma's PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD
Federal initiatives focused on PTSD and related conditions appears to validate need for new and novel approaches to mental health treatment
Silo Pharma expands into AI technology with Qwikagents asset purchase
Silo Pharma (SILO) announced a strategic business expansion into AI technology as a second line of business resulting from its recent purchase of the assets of Qwikagents.ai, an AI platform…
Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents
Launch of Dedicated AI Subsidiary Positions Company for New Revenue Streams While Advancing PTSD Program Toward Phase 1 SARASOTA, FL, April 22, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO...
Silo Pharma gets European Patent Office allowance for PTSD prevention therapy
Silo Pharma (SILO) announced that the European Patent Office has issued a Rule 71 communication indicating its intent to grant a patent for an European patent application titled “Prophylactic Efficacy...
Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy
EPO Greenlights Claims Covering Preventative use of therapy targeting 5-HT4 Pathway and Expands Silo Pharma IP Portfolio SARASOTA, FL, April 06, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SIL...
Silo Pharma announces $1M share repurchase program
Silo Pharma (SILO) announced that its board of directors has authorized a share repurchase program to acquire up to $1M of the company’s common stock. The company may purchase common…
Silo Pharma Announces Share Buyback Program
Sarasota, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psych...
Silo Pharma receives Notice of Allowance in Japan for SPC-15
Silo Pharma (SILO) announced that the Japan Patent Office has issued a Notice of Allowance for a patent application covering its lead asset, SPC-15, a novel intranasal therapeutic targeting Post-Traum...
Silo Pharma Receives Notice of Allowance in Japan for SPC-15, Expanding Global Intellectual Property Portfolio
SARASOTA, FL, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and...
Silo Pharma executes LOI with Allucent for Phase 1 development of SPC-15
Silo Pharma (SILO) entered into a non-binding Letter of Intent with Allucent to provide clinical research services for two planned Phase 1 studies evaluating its SPC-15 nasal spray in healthy…
Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15
Planned SAD and MAD Studies Mark Key Clinical Inflection Point for Intranasal PTSD and Anxiety SARASOTA, FL, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”...
Silo Pharma partners with Allucent for planned FDA IND application for SPC-15
Silo Pharma (SILO) announced that it has selected Allucent, a global full-service clinical research organization, CRO, to support the Company’s final preparations and planned submission of its investi...
Silo Pharma Partners with Allucent to Support Planned FDA Investigational New Drug Application for SPC-15 as a Therapeutic for PTSD
SARASOTA, FL, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, toda...
Silo Pharma selects AlphaLedger’s T12 Fund for tokenized RWA investments
Silo Pharma (SILO) has selected Alphaledger/Simplify Target 12% Distribution Fund as a core component of its real-world asset investment strategy on the Solana blockchain. This strategic allocation al...
Silo Pharma Selects Alphaledger's T12 Fund for Tokenized Real-World Asset Investments on Solana Blockchain
Investment vehicle provides diversified exposure to real-world assets and expected to reduce portfolio volatility Strategic allocation aligns with Silo's objective of generating yield while maintainin...
Silo Pharma provides update on SPC-15 advancement, digital asset program
Silo Pharma (SILO) announced a comprehensive update detailing progress for lead candidate SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder and stress-induced anxiety, an...
Silo Pharma Issues Update on Milestone Achievements in PTSD Drug Development and New Digital Assets Treasury Program
Significant milestones are approaching in drug development; additional digital asset purchases expected Preparation for FDA IND application expected to commence before year-end SARASOTA, FL, Oct. 23, ...
Silo Pharma announces initial Bitcoin purchase
Silo Pharma (SILO) announced its initial purchase of Bitcoin (BTC-USD) under its crypto reserve strategy targeting multi-chain asset growth. Silo’s initial purchase of Bitcoin follows recently announc...
Silo Pharma Expands Crypto Treasury with First Strategic Bitcoin Purchase Reinforcing Company's Commitment to Multi-Chain Growth
SARASOTA, FL, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, to...
Silo Pharma acquires ResearchCoin crypto tokens
Silo Pharma (SILO) announced its initial purchase of ResearchCoin as part of its expanded digital assets treasury strategy designed to capture long-term value from emerging multi-chain opportunities. ...
Silo Pharma Acquires ResearchCoin (RSC) Crypto Tokens in Support of Decentralized Science (DeSci)
Company invests in DeSci blockchain innovation and purchases native coin of ResearchHub, a decentralized science platform co-founded by Coinbase CEO, Brian Armstrong
Silo Pharma Announces Closing of $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
SARASOTA, FL, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and...